<DOC>
	<DOCNO>NCT02233777</DOCNO>
	<brief_summary>The present study conduct find whether bioavailability 150 mg pregabalin capsule produce Dexa Medica equivalent reference product ( Lyrica® capsule 150 mg , Pfizer Manufacturing Deutschland GmbH , Germany ) .</brief_summary>
	<brief_title>Bioequivalence Study Two Formulations Pregabalin Capsules 150 mg</brief_title>
	<detailed_description>This randomize , open label , two-period , two-sequence , crossover study fast condition . The participate subject require overnight fast next morning give orally one capsule test drug ( Pregabalin 150 mg produce Dexa Medica ) one capsule reference drug ( Lyrica® 150 mg , Pfizer Manufacturing Deutschland GmbH , Germany ) . Blood sample draw immediately take drug ( control ) , 20 , 40 minute , 1 , 1.5 , 2 , 2.5 , 3 , 4 , 6 , 9 , 12 , 24 , 36 hour drug administration . Seven day first drug administration ( washout period ) , procedure repeat use alternate drug . The plasma concentration pregabalin determine use validated liquid chromatography tandem mass spectrometry detection ( LC-MS/MS ) method .</detailed_description>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Male female subject absence significant disease clinically significant abnormal laboratory value laboratory evaluation , medical history , physical examination screening could consider healthy base evaluation Aged 1855 year inclusive Preferably nonsmoker smoke less 10 cigarette per day Able participate , communicate well investigator willing provide write informed consent participate study Body mass index within 18 25 kg/m2 Vital sign ( 10 minute rest ) within follow range : Systolic blood pressure : 100120 mmHg Diastolic blood pressure : 6080 mmHg Pulse rate : 6090 bpm Personal/family history allergy hypersensitivity contraindication pregabalin ally drug Pregnant lactate woman ( urinary pregnancy test apply woman subject screen take study drug ) Any major illness past 90 day clinically significant ongoing chronic medical illness e.g . congestive cardiac failure ( heart failure ) , hepatitis , hypotensive episode , hyperglycemia , etc Presence clinically significant abnormal value screen , e.g . significant abnormality liver function test ( ALT , alkaline phosphatase , total bilirubin &gt; = 1.5 ULN ) , renal function test ( serum creatinine concentration &gt; 1.4 mg/dL ) , etc Positive hepatitis B surface antigen ( HBsAg ) , antiHCV , antiHIV Clinically significant electrocardiogram ( ECG ) abnormalities Any surgical medical condition ( present history ) might significantly alter absorption , distribution , metabolism , excretion study drug , e.g . gastrointestinal disease include gastric duodenal ulcer history gastric surgery Past history anaphylaxis angiodema History drug alcohol abuse within 12 month prior screen study Participation clinical trial within past 90 day calculate last visit History bleed coagulative disorder History seizure , epilepsy , kind neurological disorder History difficulty donate blood difficulty accessibility vein leave right arm A donation loss 300 mL ( ) blood within 3 month study 's first dose day Intake prescription , nonprescription drug , food supplement , herbal medicine within 14 day study 's first dosing day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Pregabalin</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Antiepileptic</keyword>
</DOC>